Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2025 | STAR-EV: neoadjuvant enfortumab vedotin and SBRT in MIBC

Tian Zhang, MD, UT Southwestern Medical Center, Dallas, TX, discusses the Phase I/II STAR-EV trial (NCT06394570) of neoadjuvant enfortumab vedotin with stereotactic body radiotherapy (SBRT) in patients with localized, cisplatin-ineligible muscle invasive bladder cancer (MIBC). This study assesses safety, feasibility, and pathologic complete response rate prior to cystectomy. Patients receive up to three cycles of treatment with escalating timing of radiotherapy. The study also investigates pathologic downstaging, treatment-related toxicities, surgical timing, and exploratory biomarkers. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.